Five isoenzymes of protein kinase C are expressed in normal and STZ-diabetic rat hepatocytes: effect of phorbol 12-myristate 13-acetate  by Croquet, Frédéric et al.
ELSEVIER Biochimica et Biophysica Acta 1315 (1996) 163-168 
Biochi ~mic~a 
et Biophysica A~ta 
Five isoenzymes of protein kinase C are expressed in normal and 
STZ-diabetic rat hepatocytes: effect of phorbol 12-myristate 13-acetate 
Frederic Croquet, Arlette Br~hier, Sophie Gil, Jean Davy, Jeanne F~ger * 
Laboratoire de Biochimie EA 1595, Facultd de Pharmacie, rue J.B. Cldment, 92296 Ch~tenay-Malabry Cedex, France 
Received 30 June 1995; revised 7 November 1995; accepted 6 December 1995 
Abstract 
Using isoenzyme-specific antisera, five Protein Kinase Cs (PKCs) were detected in cytosol and membrane hepatocytes from normal 
rats: PKC a (80 kDa), PKC/3 II (40, 50, 55, 85 kDa), PKC S (74, 76 kDa), PKC e (95 kDa), PKC ~" (65, 70 kDa). STZ-diabetes induced a 
lower expression of the five PKCs, a higher localization in the cytosol, a preferential expression of PKC 6 as the 76 kDa phosphorylated 
species and a decreased kinase activity towards Histone III-S. A 1 /xM phorbol 12-myristate 13-acetate (PMA) incubation induced similar 
translocation tothe membrane of PKCs a, native 85 kDa /3 II and e. The 74 kDa PKC 6 was switched to the 76 kDa species, the normal 
form in STZ-diabetic ells. The truncated PKC/3 II and PKC E were unchanged. 
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1. Introduction 
Hepatocytes are involved in a variety of metabolism 
regulation and especially glucose homeostasis. In diabetes 
mellitus, they become highly gluconeogenic and ketogenic 
as a consequence of insulin deficiency. Their mechanisms 
of transduction allow them to adapt their response to 
multiple modulators. 
Protein Kinase Cs (PKCs) are major mediators of extra- 
cellular signals such as growth factors, hormones, and 
neurotransmitters [1-3]. Molecular cloning, structural and 
biochemical studies have revealed that they belong to a 
multigenic family of at least 12 isoforms which have been 
classified into three different subfamilies. The conven- 
tional cPKCs (a ,  /3 I, /3 II, y), calcium-dependent, and the 
novel nPKCs (S, E, r/ /L, 0, It), calcium-insensitive, are 
regulated by phospholipids, diacylglycerol (DAG) and tu- 
mor-promoting phorbol esters. The atypical aPKCs (~', A, 
L) are DAG, phorbol esters and are calcium-insensitive 
[2,4]. In the pathology of diabetes mellitus, PKCs were 
involved in the alterations observed in retina, heart, aorta 
Abbreviations: PKC, protein kinase C; STZ, streptozotocin; PMA, 
phorbol 12-myristate 13-acetate; SDS-PAGE, sodium dodecyl sulfate- 
polyacrylamide g l electrophoresis; DAG, diacylglycerol. 
* Corresponding author. Fax: + 33 1 46838055. 
0925-4439/96/$15.00 © 1996 Elsevier Science B,V. All rights reserved 
SSDI 0925-4439(95)00  124-7 
and renal vessels [5-7]. Their role in hepatocyte glycogen 
metabolism was shown using phorbol esters [8,9]. In stud- 
ies on diabetic rat hepatocytes compared to normal cells, 
some reports showed a decrease in PKC activity on en- 
dogenous and exogenous ubstrate [10], while others de- 
scribed selective alterations in PKC isoforms which tended 
to an increase in PKCs expression [11]. 
Since these last results were somewhat contradictory, 
we performed comparative studies on normal and STZ-di- 
abetic rats hepatocytes in order (1) to identify the expres- 
sion of PKC isoforms (2) to describe their intracellular 
localization, (3) to measure their kinase activities and (4) 
to analyze their response to PMA stimulation. 
2. Materials and methods 
2.1. Chemicals 
Antibodies (Santa Cruz Biotechnology) were raised in 
rabbits against peptides 652 to 672 (DFEGF-  
SYVNPQFVHPILQSSV) from PKCa,  657 to 673 
(EGFSFVNSEFLKPEVKS) from PKC/3II, 657 to 673 
(AFKGFSFVNPKYEQ FLE) from PKC6, 722 to 736 
(EEFKGFSYFGEDLMP) from PKCE and 574 to 592 
(EFEGFEYINPLLLSAEESV) from PKC (. These epitopes 
correspond to the last amino acids mapping at the carboxy 
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terminus in the V5 region of the PKCs. Secondary anti- 
body goat anti-rabbit IGg conjugated with horseradish 
peroxydase was from Nordic. Collagenase (type IV), strep- 
tozotocin, phenyimethylsulfonyl fluoride (PMSF), benza- 
midine, leupeptin, aprotinin, PMA, /3-glycerophosphate, 
Histone Ill-S, phosphatidylserine and diolein were from 
Sigma. Polyvinylidene difluoride membrane (PVDF), [y- 
32p]ATP (3000 Ci/mmol) were from Dupont-NEN. En- 
hanced Chemiluminescence d tection system (ECL) was 
from Amersham. Prestained molecular weight markers 
were from Bio-Rad. All other reagents were from Sigma. 
2.2. Animals 
Male Sprague-Dawley rats (180-220 g) from Charles 
River (St. Aubin, France) were rendered iabetic by i.v. 
injection of streptozotocin (65 mg/kg body wt) in citrate 
buffer (pH 4.6) and killed 11 days later. The diabetic state 
was confirmed when glycemia was over 25 mM. 
2.3. Hepatocytes preparation 
Hepatocytes were isolated by collagenase perfusion ac- 
cording to the technique of Berry and Friend [12] as 
modified by Davy et al. and Gil-Falgon et al. [13,14]. 
2.4. Treatment of hepatocytes and extraction of cytosolic 
and membrane proteins 
Hepatocytes were incubated in the HTT medium (30 
mM Hepes, 30 mM Tes, 36 mM Tricin, pH 7.4, 68 mM 
NaC1, 5.36 mM KC1, 2.5 mM CaC12, 0.64 mM MgC12, 
1.1 mM KH2PO4, 0.31 mM Na2SO 4 and 0.1% BSA) with 
or without 1 /xM PMA during 5, 30, 120 min. After 3 
washes in the HTT medium, the cells were homogenized 
in lysis buffer (20 mM Tris-HC1, pH 7.5, 10 mM EGTA, 2 
mM EDTA, 50 mM /3-mercaptoethanol, 1 mM PMSF, 2 
mM benzamidine, 20 /zg/ml leupeptin, 5 ~g/ml  apro- 
tinin) and disrupted for 1 min by Ultraturrax. The ho- 
mogenate was centrifuged for 10 rain at 1500 X g at 4°C. 
The pellet was discarded and the supernatant was cen- 
trifuged for 1 h at 100000 X g at 4°C. The supernatant, 
which contained the cytosolic proteins, was frozen in 50% 
glycerol and stocked at -80°C. The pellet was extracted 
for 1 h with the lysis buffer containing 1% Triton X-100 at 
4°C and centrifuged l h at 4°C at 100000 x g. The 
supernatant, containing the membrane proteins, was stocked 
as the cytosol. The brain homogenate was prepared at 4°C 
as follows: rats were decapitated and brains immediately 
removed, weighed, and homogenized in the lysis buffer, 
centrifuged 10 min at 1500 X g at 4°C. The pellet was 
discarded and the brain homogenate was collected and 
stocked with 50% glycerol at -80°C. Direct hepatocytes 
homogenate was prepared by mixing the cells with the 
electrophoresis sample buffer, and boiled for 5 min. The 
homogenate was centrifuged at 1500 × g during 10 min 
and the supernatant was kept. Protein concentration was 
determined using the colorimetric assay of Lowry [15]. 
2.5. Western blot analysis 
30 /zg of cytosolic and membrane proteins were sub- 
jected to 8.5% SDS-PAGE analysis (Bio-Rad) according to 
the method of Laemmli [16] and transferred to PVDF 
membrane. Non-specific binding sites were blocked by 
incubation with 10% skimmed milk in Tris buffer (20 mM 
Tris-HC1 (pH 7.5), 0.5 M NaC1, 0.05% Tween 20) for 1 h 
at 37°C or overnight at 4°C. The PVDF sheets were 
incubated with the respective PKC antisera (a ,  /3 II, 6, e 
and ~') at 1/1000 dilution in 0.5% dry milk in Tris buffer 
for 1 h at room temperature. After 5 washes with the Tris 
buffer, the secondary antiserum (Goat anti-rabbit IGg con- 
jugated with horseradish peroxydase, diluted 1 / 100 000 in 
0.5% skimmed milk in Tris buffer) was added and incu- 
bated for 1 h at room temperature. The above washing 
procedure was repeated. The immunoreactive bands were 
visualized by the ECL system onto Kodak AR5 X-OMAT 
film. The films were quantified by densitometry. 
Specificities of immunoblotting were verified by run- 
ning the different extracts in the presence of appropriate 
antigenic peptides. For these tests, a ratio of 10 /zg peptide 
for 1 /zg antibody were incubated 1 h at 37°C before 
blotting. 
2.6. PKC activiO' 
Both cytosol and membrane fractions were incubated in 
150/xl of a medium containing 20 mM Tris-HC1 (pH 7.5), 
10 mM MgCI 2, 50 mM /3-glycerophosphate, 1 mM EDTA, 
5 mM EGTA, 100 /xM ATP, 1.5 /xCi [y-32p]ATP (3000 
Ci/mmol) and 75 /xg Histone type III-S as the specific 
substrate. This incubation gave the basal level of phospho- 
rylation. Then the specific PKC activity was measured in 
the presence of specific activators uch as 6.2 mM CaC12, 
13 /xg phosphatidyiserine and 0.4/xg diolein. The reaction 
was initiated by adding ATP and was stopped by spotting 
a 100 /xl aliquot onto Whatman 3 MM paper and washing 
5 times in 10% trichloroacetic a id for 10 min. Radioactiv- 
ity was counted by Cherenkov method using a Packard 
2200 CA Tri-carb. 
3. Results and discussion 
In order to describe which isoforms of PKC were 
present in normal and diabetic rat hepatocytes, Western 
blots of cytoplasmic and membrane proteins were im- 
munostained with antibodies pecific for individual iso- 
forms. Immunoreactive bands were considered specific 
when successfully competed with the respective peptide 
antigen. Since the antisera have different affinities for their 
peptide antigens and for the corresponding PKC isoforms, 
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Fig. 1. Western blot analysis of PKC a ,  fl II, 6, E and ~" in normal and diabetic rats hepatocytes. Normal and diabetic rats hepatocytes were incubated for 
0, 5, 30, 120 min with 1 #M PMA. Cytosol (C) and membrane (M) were subjected to SDS-PAGE and subsequently immunoblotted with isoform-specific 
PKC antisera. The use of a competiting peptide is shown (C /M + peptide). For PKC/3 II: B corresponds to an homogenate of normal rat brain and H 
corresponds to an homogenate of normal or diabetic hepatocytes. This is the typical result of at least 3 independent experiments. 
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Fig. 2. Statistical analysis of the distribution of PKC a, 6, E and ~" 
between membrane and cytosol compartments of normal (N) and diabetic 
(D) hepatocytes, Membrane (Mb) and cytosol (Cy) samples isolated from 
rat hepatocytes were analysed by SDS-PAGE with subsequent immuno- 
blotting using PKC isoform-specific antisera s described in Section 2. 
Scanning densitometry of immunoreactive bands allowed for the estima- 
tion of comparative changes in the level of PKC isoforms occuring upon 
induction of STZ-diabetes. The percentages indicate the increase or 
decrease in PKC isoform levels in compartments of diabetic hepatocytes 
compared to control animals (cytosol+membrane = 100%). Errors are 
-+-S.E.M. for 3-7 separate experiments using cell preparations from 
different animals. 
comparisons cannot be made among antisera, but compara- 
tive estimations can be proposed for cytosolic and mem- 
brane extracts for a given isoform. 
3.1. Identification and intracellular distribution of five 
PKC isoforms in normal rat hepatocytes 
In isolated hepatocytes, we provided evidence of the 
presence of the five ce, /311, 6, E and ff isoforms (Fig. 1), 
while PKCy, which is known as being preferentially lo- 
cated in neurons [1,2,17], was absent (data not shown). 
Tang et al. [11] showed the presence of only four isoen- 
zymes a, /3 II, c and ~', while in liver homogenates only 
the c~, S and ~" isoenzymes were reported [17]. 
The PKC a isoform was mainly localized in the cytosol 
fraction of hepatocytes, although a lower signal was de- 
tectable in the membrane compartment (Fig. 2). The ob- 
served molecular size of 80 kDa (Fig. 1) was consistent 
with other reports, in liver homogenate [17], in glioblas- 
toma 328 cells [18], or after transfection i COS cells [19]. 
However, a supplementary higher molecular form at 90 
kDa was reported [11] that we did not detect. This discrep- 
ancy may be due to the use of different antibodies. 
Four forms of PKC/3 II were expressed in the normal 
hepatocytes: two major ones at 55 and 40 kDa and two 
minor ones at 85 and 50 kDa. The 40, 50 and 55 kDa 
forms were equally distributed between cytosolic and 
membrane xtracts, while the 85 kDa was mainly cytoso- 
lic. A molecular size of 85 kDa has been reported by many 
authors for PKC/3 II in different cellular types [17,20]. In 
the cytosolic fraction of hepatocytes, only 82 kDa PKC/3 II 
was observed by Tang et al. [11]; Alesenko et al. did not 
detect any PKC/3 II in liver [21], while Fujihara et al. [22] 
reported the presence of 80, 69 and 39 kDa proteins in a 
macrophage cell line. Since the antibodies we used were 
raised against he COOH terminal region, the smaller sizes 
we observed could represent proteolytic fragments of 
PKC/3II, containing the catalytic domain and conse- 
quently constitutively active. So as to determine whether 
there was no PKC degradation during the protein extrac- 
tion protocol, we realized a rapid homogenization of the 
hepatocytes in the electrophoresis denaturing buffer with 
boiling for 5 min. The 85, 55 and 40 kDa immunoreactive 
PKC/3 II were still present, suggesting that these different 
forms of PKC/3 II are naturally occurring. An homogenate 
of rat brain used as a control proved the veracity of our 
immunoblotting method, with the detection of the 85 kDa 
PKC/3II as observed by others [17] and the lack of 
proteolysis using the same experimental conditions. 
Two forms of PKC6 (74-76 kDa) were detected in 
both the cytosol and membrane extracts. A similar doublet 
was already described in Kupffer cells [23] and in rat 
fibroblasts [24]. They represent unphosphorylated and 
phosphorylated forms of PKC 6 [25]. 
The PKC e (95 kDa) was present in both cellular com- 
partments, while previous reports showed its presence in 
membrane fractions only [11], or its absence in the liver 
[171. 
Two PKC ( were detected at 65 kDa and 70 kDa. Many 
authors observed higher molecular sizes of 72-80 kDa in 
various cellular types [24,26-29]; but Ono et al. reported a
64 kDa PKC( from rat brain cDNA expressed in COS 
cells [30]. 
3.2. Modifications induced by STZ-diabetes in PKC iso- 
forms in rat hepatocytes 
The main differences due to STZ-diabetes resided in a 
lower expression of PKCS and PKCE in both cellular 
compartments (Fig. 2). Interestingly, PKC6 was mainly 
the 76 kDa phosphorylated forms (Fig. 1). A diminution of 
PKCE was detected in the STZ-diabetic cytosol with 
apparition of truncated forms. Concerning PKC a, its level 
in the cytosol was slightly lower than in normal hepato- 
cytes (Fig. 2). For PKC/3 II, the three forms were observed 
at 55, 50, and 40 kDa as in normal cells, while the native 
85 kDa was not detectable. The rapidly boiled homogenate 
prepared from STZ-diabetic hepatocytes showed the pres- 
ence of the same three low molecular size of PKCs/3 II, 
with a weakly detectable 85 kDa species, showing that a 
slight degradation may have occurred during the experi- 
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Table 1 
PKC activity in normal cytosol hepatocytes 
PL + Ca 2 + PL Ca 2 + Control 
CPM 6639±564 1729± 164 1663±49 1317_+41 
% of control 504* * * 131 * * 126. * 100 
Cytosol was incubated for 5 min with [3 `-32 P]ATP, using Histone III-S as 
substrate; with or without cofactors: PL (phosphatidylserine+diolein), 
Ca 2+ or PL+Ca 2+. Values represent the means for 3 rats. Significantly 
different o control: * * P < 0.01, * • * P < 0.001 (analysis of variance 
test). 
mentation. In contrast, an important degradation seemed to 
occur in the rat in vivo, resulting from specific hepatocytes 
characteristics. As a regulatory process, some variations of 
Ca 2+ may take place, which are very important for the 
many metabolic adaptations of the hepatocytes and critical 
for the activation of proteolytic enzymes uch as calpain, 
well known for their action towards PKC [31,32]. Concern- 
ing PKC~', there was the same distribution and the same 
level of expression as in normal hepatocytes (Fig. 2). 
The differences we observed in the STZ-diabetic hepa- 
tocytes between our results and those reported by Tang et 
al. [11] were in agreement with the discrepancies already 
mentioned in the normal rat. Our results, rather in favor of 
a general decrease of expression of PKCs in STZ-diabetic 
hepatocytes, led to the determination of kirlase activity. 
3.3. Kinase acti~,it3' of PKC in normal and STZ-diabetic 
rats hepatocytes 
In order to determinate what kind of PKCs were acti- 
vated in our PKC assay, the measures were performed with 
or without cofactors. The results in Table 1 show that the 
phospholipids or calcium, alone, provided an activation of 
the phosphorylation f Histone III-S used as substrate, but 
dramatically weaker than in the presence of phospholipids 
and calcium together. We can consider that the activity 
measured in the presence of all co-factors mainly corre- 
sponds to cPKC. The cPKC activity was mostly located in 
the cytosol fraction of both normal and diabetic hepato- 
cytes (Table 2). These results are in agreement with other 
reports [33.34]. The main difference between normal and 
Table 2 
Subcellular distribution of PKC activity in normal and diabetic rats 
hepatocytes 
Cytosol i Membrane 
Normal 1.92+0.21 0.72+0.1 t 
Diabetic 1.04 ± 0.15 0.43 ± 0.10 
Cytosolic and membrane fractions were incubated lbr 5 min with [3'- 
32p]ATP, using Histone III-S as the substrate. The PKC activity was the 
difference between incubations with or without PKC activatores. VaLues, 
expressed as nmol of phosporylated Histone III-S per min per mg protein, 
represent the means for 3 -4  rats. 
nmol phosphorylated Histone III-S ra in-  l mg ~ protein. 
diabetic hepatocytes resided in a decrease of 47% and 43% 
in the cytosolic and membrane fractions respectively, co- 
herent with previous report by Pugazhenthi [10]. 
3.4. Regulation of hepatocytes PKC isoenzymes by the 
phorbol ester PMA 
To test whether a pathology such as STZ-diabetes mod- 
ifies PKCs responses to phorbol esters, we performed 
kinetic incubations with 1 #M PMA up to 2 h. 
Results were very similar for normal and STZ-diabetic 
rats hepatocytes concerning PKC c~, /3 II, • and ( (Fig, 1). 
Cytosolic PKCo~ translocated to the membrane and was 
down-regulated after a 2-h incubation. The native 85 kDa 
cytosolic PKC/3II, although almost undetectable in con- 
trols, appeared at the membrane after a 5-rain PMA treat- 
ment and was completely down-regulated within 2 h in 
normal hepatocytes. The lower molecular size forms of 
PKC/3II were PMA resistant in both the normal and 
STZ-diabetic rats hepatocytes, which is in agreement with 
the fact that they are truncated forms missing the C1 
phorbol ester binding domain. The 95 kDa PKC • disap- 
peared from the cytosol without any increase in the mem- 
brane extracts, suggesting a dynamic translocation with a 
concomitant degradation. In addition, the slight down-reg- 
ulation obtained in the membrane after a 2-h incubation 
with PMA was in agreement with the work of Mischak et 
al. and Strulovici et al. concerning the resistance to down- 
regulation, even after a 24-h exposure to 1 /xM of phorbol 
ester in thymocytes and in NIH-3T3 [35,36]. PKC(  was 
PMA-insensitive since this atypical PKC is unable to 
recognize DAG or phorbol esters [30]. 
The only slight difference between STZ-diabetic rat 
hepatocytes compared to normal ones resided in PKC6. 
Under PMA treatment, normal hepatocytes exhibited an 
increased expression of the 76 kDa phosphorylated PKC 6, 
concomitant with the decrease of the 74 kDa PKC6 in 
both the cellular compartments. A similar result has al- 
ready been reported in the presence of 12-O-tetradecanoyl 
phorbol 13-acetate (TPA) as phorbol ester [24]. This sug- 
gests that PKC6 may be itself a substrate of PKCs. 
Besides, PKC 6 may be regulated by a phosphorylation  
a tyrosine under TPA activation [37]. In STZ-diabetic rat 
hepatocytes, a 5-rain PMA treatment induced the rapid 
disappearance of the cytosolic 74 kDa PKC 6. In addition, 
in both normal and STZ-diabetic rat hepatocytes, PMA 
provoked the translocation of the 76 kDa PKC 6 from the 
cytosol to the membrane, followed by a down-regulation 
after a 2-h treatment. 
The existence of at least 5 PKC isoenzymes in hepato- 
cytes may well reflect the various metabolic functions of 
these cells and the necessity of their rapid adaptation to 
environmental conditions. Not only can they regulate cy- 
tosolic metabolic functions, but they are also implicated in 
liver regeneration or hepatocyte proliferation [38,39]; they 
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are reported to interact with cytoskeletal elements associ- 
ated with particulate fractions of various cell types [40-44] 
and may play a role in trafficking regulations. The fact that 
diabetes induces differences in PKC isoenzymes intra- 
cellular distribution and kinase activity could be a promis- 
ing open field for further studies on some specific endoge- 
nous substrates of PKCs responsible for some altered 
hepatocyte functions in diabetes. 
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